Join us on June 4th at 6:30pm CT (7:30pm ET) with @eFFECTOR_Rx, featuring Dr. Sarat Chandarlapaty, highlighting data from Phase 2 expansion cohorts evaluating its eIf4A inhibitor #zotatifin, being presented at ASCO 2023.
Register here: lifesci.events/effector$EFTR
@steve_worland, CEO of @eFFECTOR_Rx, discusses the company’s new class of therapies, how they target a central node where two major cancer signaling pathways converge, and how they pack the punch of a combination therapy in a single drug.
soundcloud.com/levine-media-…